[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532374":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":20,"responsibleParty":33,"collaborators":36,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":82,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":20},{"fullName":5,"class":6},"Dalhousie University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL","In this study, there is only one study arm, and all eligible participants will be assigned to a treatment group and will participate in three treatment sessions of the OpiVenture program, in addition to the Opioid therapy agonist treatment they are receiving through the recruiting clinic.",[13],"Behavioral: OpiVenture",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BEHAVIORAL","OpiVenture","OpiVenture, a targeted psychosocial intervention, complements opioid agonist therapy for opioid use disorder. Adapted from proven interventions like PreVenture, it unfolds over three sessions. Session one covers introductions, an ice-breaker, trait overview, strengths\u002Flimitations discussion, goal setting, and homework. Session two reviews homework, explores coping strategies, weighs alternatives, introduces \"hot thoughts,\" reviews trait-specific hot thoughts, and assigns homework. The concluding session involves reviewing homework, identifying personal hot thoughts, challenging them through a cognitive-behavioral exercise, applying insights to goal setting, and concluding with a wrap-up.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Sherry Stewart, PhD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","902-494-3793","sstewart@dal.ca",{"name":31,"role":27,"phone":20,"phoneExt":20,"email":32},"Neda Alizadeh, PhD","neda.alizadeh@dal.ca",{"type":24,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Sherry Stewart","Principal Investigator",[37,40,43,45,47,49,51],{"name":38,"class":39},"Canadian Institutes of Health Research (CIHR)","OTHER_GOV",{"name":41,"class":42},"Direction 180 | Nova Scotia Mental Health and Addictions","UNKNOWN",{"name":44,"class":42},"Centre for Research, Education, and Clinical Care of At-Risk Populations (RECAP)",{"name":46,"class":42},"River Stone Recovery Centre",{"name":48,"class":6},"Centre de Recherche du Centre Hospitalier de l'Université de Montréal",{"name":50,"class":6},"Université de Montréal",{"name":52,"class":6},"University of New Brunswick","100532374","the-feasibility-of-the-opiventure-program-for-clients-undergoing-opioid-agonist-therapy-100532374",false,"NCT06211972","The Feasibility of the OpiVenture Program for Clients Undergoing Opioid Agonist Therapy","Personality-Targeted Interventions for Addressing Polysubstance Use Among Opioid-Addicted Clients Undergoing Opioid Agonist Therapy: A Feasibility Study","Inclusion Criteria:\n\nCurrently enrolled in Opioid Agonist Therapy at one of the 4 partner clinics in Quebec and Atlantic Canada for 30 days\n\n≥18 years of age Score at least one standard deviation (SD) above the population-specific norm on 1 of 4 personality traits on the Substance Use Risk Profile Scale (SURPS ) Ability to understand spoken English or French Ability to provide informed consent\n\nExclusion Criteria:\n\nThose who are unable to provide informed consent and indicate severe cognitive impairment -measured by the Mini-Mental State Examination (MMSE), will be excluded.","ALL","18 Years",{"count":63,"type":64},96,"ESTIMATED","INTERVENTIONAL",[67],"NA","The opioid crisis continues its devastating impact on Canada, with over 13,900 deaths recorded between 2016 and 2019. Dangerous prescription opioid usage persists, affecting 12.3% of Canadians in 2018. The crisis has escalated, particularly during the COVID-19 pandemic, resulting in increased mortality rates. While opioid agonist therapy (OAT) is a common treatment, it falls short in addressing concurrent polysubstance use, a prevalent issue in OAT clients. Recognizing the limitations of OAT alone, there is a growing recommendation to supplement it with psychosocial interventions.\n\nThe PreVenture program, known for its efficacy in reducing substance use, has been adapted for OAT clients, termed \"OpiVenture.\" This study aims to comprehensively assess OpiVenture's feasibility and limited efficacy within an OAT setting. Utilizing a mixed-methods approach, the study design integrates qualitative and quantitative data collection methods to thoroughly evaluate the program's feasibility and preliminary effectiveness. The focus extends beyond immediate outcomes, encompassing the preparation for future randomized controlled trials, including considerations for sample size calculation and recruitment effectiveness. This research addresses the urgent need for more comprehensive interventions to mitigate opioid use disorder (OUD) and associated morbidity, offering a potential solution to improve OAT retention and reduce mortality rates.",[70,71,72],"Opioid Use Disorder","Polysubstance Addiction","Substance Use",[74,75,76,77,78,79,80,81],"Anxiety sensitivity","Hopelessness","Sensation-seeking","Impulsivity","Personality","Psychosocial Interventions","Feasibility","Opioid Agonist Therapy","NOT_YET_RECRUITING","2024-07-26",{"date":85,"type":86},"2024-07-30","ACTUAL",{"date":88,"type":64},"2024-10-15",{"date":90,"type":64},"2026-02-01",{"name":5,"class":6}]